CD8A and COVID-19: This result demonstrates the specificity of the antiviral CD8+ T cell response incited against SARS-CoV-2, indicating that cross-reactivity, if existent, may be restricted and grant protection of HLA-A*02+ individuals against severe cases of COVID-19 but not against SARS-CoV-2 infection (42, 43).